Lack of adenosine A1 and dopamine D2 receptor-mediated modulation of the cardiovascular effects of the adenosine A2A receptor agonist CGS 21680

European Journal of Pharmacology

Volumn 484, Issue 2-3, 2004, Pages 269-275

  Schindler, Charles W ^a   Karcz Kubicha, Marzena ^a   Thorndike, Eric B ^a   Müller, Christa E ^b   Tella, Srihari R ^c   Goldberg, Steven R ^a   Ferré, Sergi ^a  

^a DHHS   (United States)

^b UNIVERSITY OF BONN   (Germany)

^c Drug Enforcement Administration   (United States)

Author keywords

Adenosine A1 receptor; Adenosine A2A receptor; Cardiovascular; Dopamine D2 receptor; Motor activity

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3 (3 HYDROXYPROPYL) 8 (2 METHOXYSTYRYL) 7 METHYL 1 PROPARGYLXANTHINE PHOSPHATE DISODIUM; 6 N CYCLOPENTYLADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; MSX 3; QUINPIROLE; UNCLASSIFIED DRUG; ADENOSINE; ADENOSINE A2A RECEPTOR; CARDIOVASCULAR AGENT; DRUG DERIVATIVE; PHENETHYLAMINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG PROTEIN BINDING; HEART CONTRACTION; HEART RATE; MALE; MODULATION; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; STATISTICAL SIGNIFICANCE; ANIMAL; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG EFFECT; LOCOMOTION; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ADENOSINE; ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR AGENTS; HEART RATE; LOCOMOTION; MALE; PHENETHYLAMINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D2;

EID: 1642546394     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.11.010     Document Type: Article

References (37)

1. 6-cyclopentyladenosine and 8-cyclopentyltheophylline. Br. J. Pharmacol. 115:1995;1253-1259.
2. Barraco R.A., el-Ridi M.R., Ergene E., Phillis J.W. Adenosine receptor subtypes in the brainstem mediate distinct cardiovascular response patterns. Brain Res. Bull. 26:1991;59-84.
3. 2A receptors on soma and central terminals of rat vagal afferent neurons. Brain Res. 652:1994;137-144.
4. 2A receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 353:1994;261-271.
5. El Yacoubi M., Ledent C., Parmentier M., Costentin J., Vaugeois J. SCH 58261 and ZM 241385 differentially prevent the motor effects of CGS 21680 in mice: evidence for a functional 'atypical' adenosine A(2A) receptor. Eur. J. Pharmacol. 401:2000;63-77.
6. Evoniuk G., von Borstel R.W., Wurtman R.J. Antagonism of the cardiovascular effects of adenosine by caffeine or 8-(p-sulfophenyl) theophylline. J. Pharmacol. Exp. Ther. 240:1987;232-428.
7. Ferré S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology. 133:1997;107-120.
8. Ferré S., Rubio A., Fuxe K. Stimulation of adenosine A2 receptors induces catalepsy. Neurosci. Lett. 130:1991;162-164.
9. Ferré S., Fredholm B.B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20:1997;482-487.
10. 2A-dopamine D2 receptor interactions in the striatum. Implications for drug therapy in neuro-psychiatric disorders and drug abuse. Curr. Med. Chem. - Central Nervous System Agents. 3:2003;1-26.
11. 2A receptors and dopamine D2 receptors. J. Biol. Chem. 277:2002;18091-18097.
12. Horvitz J.C., Williams G., Joy R. Time-dependent actions of D2 family agonist quinpirole on spontaneous behavior in the rat: dissociation between sniffing and locomotion. Psychopharmacology. 154:2001;350-355.
13. Hutchison A.J., Webb R.L., Oei H.H., Ghai G.R., Zimmerman M.B., Williams M. CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity. J. Pharmacol. Exp. Ther. 251:1989;47-55.
14. 2A receptor ligand. J. Nucl. Med. 41:2000;345-354.
15. Jackson E.K., Herzer W.A., Suzuki F. KF17837 is an A2 adenosine receptor antagonist in vivo. J. Pharmacol. Exp. Ther. 267:1993;1304-1310.
16. 2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology. 28:2003;1281-1291.
17. 2A receptor-mediated striatal expression of c-fos. Eur. J. Neurosci. 18:2003;296-302.
18. Lappe R.W., Sheldon J.H., Cox B.F. Selective adenosine-2 agonist produces both direct and reflex tachycardia in normotensive rats. J. Cardiovasc. Pharmacol. 19:1992;460-463.
19. Lawrence A.J., Krstew E., Jarrott B. Functional dopamine D2 receptors on rat vagal afferent neurones. Br. J. Pharmacol. 114:1995;1329-1334.
20. Lawrence A.J., Krstew E., Jarrott B. Adenosine-dopamine receptor interactions in the isolated rat nodose ganglion but not in membranes of dorsal vagal complex. Naunyn-Schmiedeberg's Arch. Pharmacol. 355:1997;303-308.
21. 2A adenosine receptor agonist CGS 21680C in conscious normotensive rats. Br. J. Pharmacol. 114:1995;761-768.
22. Mathot R.A., Gubbens-Stibbe J.M., Soudijn W., Jacobson K.A., Ijzerman A.P., Danhof M. Quantification of the in vivo potency of the adenosine A2 receptor antagonist 8-(3-chlorostyryl)caffeine. J. Pharmacol. Exp. Ther. 275:1995;245-253.
23. 2A adenosine receptor antagonist, SCH 58261, in the rat. J. Pharmacol. Exp. Ther. 285:1998;9-15.
24. 2A adenosine receptor antagonists-future drugs for Parkinson's disease? Drugs Future. 25:2000;1043-1052.
25. Nikodijevic O., Daly J.W., Jacobson K.A. Characterization of the locomotor depression produced by an A2-selective adenosine agonist. FEBS Lett. 261:1990;67-70.
26. Nikodijevic O., Sarges R., Daly J.W., Jacobson K.A. Behavioral effects of A1- and A2-selective adenosine agonists and antagonists: evidence for synergism and antagonism. J. Pharmacol. Exp. Ther. 259:1991;286-294.
27. 2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology. 17:1997;82-91.
28. 2A receptors in the rat central nervous system. J. Comp. Neurol. 401:1998;163-186.
29. Sauer R., Maurinsh J., Reith U., Fulle F., Klotz K.N., Muller C.E. Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists. J. Med. Chem. 43:2000;440-448.
30. Scislo T.J., Kitchen A.M., Augustyniak R.A., O'Leary D.S. Differential patterns of sympathetic responses to selective stimulation of nucleus tractus solitarius purinergic receptor subtypes. Clin. Exp. Pharmacol. Physiol. 28:2001;120-124.
31. Shryock J.C., Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am. J. Cardiol. 79:1997;2-10.
32. Spyer K.M., Thomas T. A role for adenosine in modulating cardio-respiratory responses: a mini-review. Brain Res. Bull. 53:2000;121-124.
33. St. Lambert J.H., Dashwood M.R., Spyer K.M. Role of brainstem adenosine A1 receptors in the cardiovascular response to hypothalamic defence area stimulation in the anaesthetized rat. Br. J. Pharmacol. 117:1996;277-282.
34. 2A receptors. Nucl. Med. Biol. 24:1997;187-191.
35. Tabrizchi R. Effects of adenosine and adenosine analogues on mean circulatory filling pressure and cardiac output in anesthetized rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 356:1997;69-75.
36. Tabrizchi R., Bedi S. Pharmacology of adenosine receptors in the vasculature. Pharmacol. Ther. 91:2001;133-147.
37. Tella S.R., Schindler C.W., Goldberg S.R. Cardiovascular responses to cocaine self-administration: acute and chronic tolerance. Eur. J. Pharmacol. 383:1999;57-68.